 |
449 Diseases |  |
58 Trials |
|
58 Trials |  |
3605 News |  |
| «12345678910111213...2425» |
- || Sitoiganap (ERC1671) / Epitopoietic Research Corp
Enrollment closed: ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme (clinicaltrials.gov) - Jul 21, 2021
P2, N=84, Active, not recruiting, Sponsor: University of California, Irvine
Recruiting --> Active, not recruiting
- |||| Leukine (sargramostim) / Sanofi
Clinical data, Checkpoint inhibition: Clinical data on sargramostim. We are grateful to all of the researchers and patients who made this work possible. @ATarhiniMDPhD "Sargramostim and immune checkpoint inhibitors: combinatorial therapeutic studies in metastatic melanoma" https://t.co/nWT1RltFuB (Twitter) - Jul 12, 2021
- | Leukine (sargramostim) / Partner Therap, SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
Trial completion date, Metastases: Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors (clinicaltrials.gov) - Jul 7, 2021
P1, N=10, Recruiting, Sponsor: Roswell Park Cancer Institute
Recruiting --> Active, not recruiting Trial completion date: Jun 2023 --> Jun 2024
- | Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Trial primary completion date, Surgery: Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Jul 6, 2021
P1, N=18, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jun 2023 --> Jun 2024 Trial primary completion date: Jun 2021 --> Oct 2021
- | Leukine (sargramostim) / Partner Therap
Trial primary completion date: Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401) (clinicaltrials.gov) - Jun 22, 2021
P2, N=203, Active, not recruiting, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Trial primary completion date: Jun 2021 --> Oct 2021 Trial primary completion date: Aug 2021 --> Jun 2020
- | Recentin (cediranib) / AstraZeneca
Trial completion date, Trial primary completion date, Monotherapy, Metastases: Sunitinib or Cediranib for Alveolar Soft Part Sarcoma (clinicaltrials.gov) - Jun 21, 2021
P2, N=34, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Aug 2021 --> Jun 2020 Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
- ||| Leukine (sargramostim) / Partner Therap
Trial completion: iLeukPulm: Study of Sargramostim in Patients With COVID-19 (clinicaltrials.gov) - Jun 21, 2021
P2, N=122, Completed, Sponsor: Partner Therapeutics, Inc.
Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022 Active, not recruiting --> Completed
- | BiovaxID (dasiprotimut-T) / National Cancer Institute, Accentia
Trial completion, Trial completion date: Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma (clinicaltrials.gov) - Jun 18, 2021
P2, N=26, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Trial completion date: Jun 2022 --> Jun 2021 | Active, not recruiting --> Completed
- | BiovaxID (dasiprotimut-T) / National Cancer Institute, Accentia
Trial completion date: Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma (clinicaltrials.gov) - Jun 16, 2021
P2, N=26, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jun 2022 --> Jun 2021 | Active, not recruiting --> Completed Trial completion date: Jun 2021 --> Jun 2022
- || Leukine (sargramostim) / Sanofi, UV1 / Ultimovacs
Clinical, P1 data, Journal: Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer. (Pubmed Central) - Jun 16, 2021
These results provide a rationale for further clinical studies in NSCLC with UV1 vaccination in combination with immune checkpoint blockade. https://www.clinicaltrials.gov, identifier NCT0178909.
- || Neupogen (filgrastim) / Kyowa Kirin, Amgen, Neulasta (pegfilgrastim) / Amgen, Kyowa Hakko Kirin, Roche
Review, Journal: Repurposing Pharmaceuticals Previously Approved by Regulatory Agencies to Medically Counter Injuries Arising Either Early or Late Following Radiation Exposure. (Pubmed Central) - May 28, 2021
A large number of additional agents approved by various regulatory authorities for given indications are currently under investigation for dual use for acute radiation syndrome or for delayed pathological effects of acute radiation exposure. The process of drug repurposing, however, is not without its own set of challenges and limitations.
- | Leukine (sargramostim) / Partner Therap, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Trial completion date, Trial primary completion date: NCI-2018-03732: Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma (clinicaltrials.gov) - May 27, 2021
P2, N=45, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
The process of drug repurposing, however, is not without its own set of challenges and limitations. Trial completion date: Jun 2021 --> Dec 2021 | Trial primary completion date: Jun 2021 --> Dec 2021
- | Leukine (sargramostim) / Partner Therap
New P2 trial: SESAD: Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer's Disease (clinicaltrials.gov) - May 26, 2021
P2, N=42, Not yet recruiting, Sponsor: University of Colorado, Denver
- ||||| Leukine (sargramostim) / Sanofi
Clinical: #Parkinsons research news at @UNMC "In layman's terms, problems such as stiffness, walking properly, trouble getting up from a chair--all of these have been much alleviated," said Mr. Eisenberg, a patient in the study taking Leukine for more than 2 years. https://t.co/LNdHx6qKdf (Twitter) - May 19, 2021
- | UV1 / Ultimovacs
Trial primary completion date, Combination therapy, Metastases: Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma (clinicaltrials.gov) - May 17, 2021
P1/2, N=12, Active, not recruiting, Sponsor: Ultimovacs ASA
Trial completion date: Jun 2021 --> Dec 2021 | Trial primary completion date: Jun 2021 --> Dec 2021 Trial primary completion date: Feb 2020 --> Feb 2025
- | Leukine (sargramostim) / Partner Therap, Danyelza (naxitamab) - Y / mAbs Therap
Enrollment closed: Study of Chemoimmunotherapy for High-Risk Neuroblastoma (clinicaltrials.gov) - Apr 29, 2021
P2, N=48, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Feb 2020 --> Feb 2025 Recruiting --> Active, not recruiting
- Keytruda (pembrolizumab) / Merck (MSD), Leukine (sargramostim) / Sanofi, UV1 / Ultimovacs
[VIRTUAL] A phase I clinical trial investigating the telomerase vaccine UV1 in combination with pembrolizumab in patients with advanced melanoma. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2677;
P1
Updated data with minimum 18 months follow-up will be presented at the conference . Cohort 2 results will be presented at a later stage.
- Leukine (sargramostim) / Sanofi, GP2 / Greenwich LifeSci
[VIRTUAL] A prospective, randomized, multicenter, double-blinded, placebo-controlled phase III trial of the HER2/neu peptide GP2 + GM-CSF versus bacteriostatic saline/WFI placebo as adjuvant therapy after any trastuzumab-based therapy in HER2-positive women with operable breast cancer. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1700;
To monitor for any unexpected adverse events and toxicities related to GP2 therapy . Accrual: The target enrollment is up to approximately 500 patients.
- Leukine (sargramostim) / Sanofi, Herceptin (trastuzumab) / Roche
[VIRTUAL] Final five-year median follow-up safety data from a prospective, randomized, placebo-controlled, single-blinded, multicenter, phase IIb study evaluating the use of HER2/neu peptide GP2 + GM-CSF vs. GM-CSF alone after adjuvant trastuzumab in HER2 positive women with operable breast cancer. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1640;
P2
The majority of patients experienced only mild local and systemic toxicities . Importantly, toxicities in the GP2+GM-CSF group were comparable to those seen in the GM-CSF only group, suggesting the toxicities are attributable to GM-CSF.
- || Leukine (sargramostim) / Partner Therap, NeuVax (nelipepimut-S) / Dr. Reddy's, Herceptin (trastuzumab) / Roche
Trial completion date, Trial primary completion date: Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients (clinicaltrials.gov) - Apr 26, 2021
P2, N=100, Active, not recruiting, Sponsor: Cancer Insight, LLC
Importantly, toxicities in the GP2+GM-CSF group were comparable to those seen in the GM-CSF only group, suggesting the toxicities are attributable to GM-CSF. Trial completion date: Mar 2021 --> Dec 2021 | Trial primary completion date: Mar 2021 --> Dec 2021
- || Leukine (sargramostim) / Partner Therap, NN1213 / Novo Nordisk
Trial completion: The Immuno-Response to Primary Cryotherapy for the Treatment of Prostate Cancer (clinicaltrials.gov) - Apr 23, 2021
P1, N=19, Completed, Sponsor: University of Colorado, Denver
Trial completion date: Mar 2021 --> Dec 2021 | Trial primary completion date: Mar 2021 --> Dec 2021 Active, not recruiting --> Completed
- |||| Keytruda (pembrolizumab) / Merck (MSD), Leukine (sargramostim) / Partner Therap
New P2 trial, IO biomarker: A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy (clinicaltrials.gov) - Apr 23, 2021
P2, N=83, Not yet recruiting, Sponsor: Tufts Medical Center
- | Leukine (sargramostim) / Sanofi
Journal: Sargramostim (rhu GM-CSF) Improves Survival of Non-Human Primates with Severe Bone Marrow Suppression after Acute, High-Dose, Whole-Body Irradiation. (Pubmed Central) - Apr 23, 2021
Neutrophil, platelet and lymphocyte recovery rates were accelerated and infection rates decreased. Improved survival when sargramostim was started 48 h postirradiation, without use of intensive supportive care, suggests sargramostim may be effective in treating humans exposed to acute, high-dose whole-body, ionizing radiation in a scenario such as a mass casualty event.
- | Leukine (sargramostim) / Partner Therap
Trial completion date, Trial primary completion date, Immunomodulating: GM-CSF for Immunomodulation Following Trauma (GIFT) Study (clinicaltrials.gov) - Apr 22, 2021
P4, N=200, Active, not recruiting, Sponsor: Mark Hall
Improved survival when sargramostim was started 48 h postirradiation, without use of intensive supportive care, suggests sargramostim may be effective in treating humans exposed to acute, high-dose whole-body, ionizing radiation in a scenario such as a mass casualty event. Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021
- |||| Leukine (sargramostim) / Partner Therap
Enrollment open: Sargramostim Use in COVID-19 to Recover Patient Health (clinicaltrials.gov) - Apr 5, 2021
P2b, N=400, Recruiting, Sponsor: Partner Therapeutics, Inc.
Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021 Not yet recruiting --> Recruiting
- || Torisel (temsirolimus) / Pfizer, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Enrollment closed: Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma (clinicaltrials.gov) - Mar 30, 2021
P2, N=73, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Completed --> Active, not recruiting
- || Leukine (sargramostim) / Sanofi, Ghent University Hospital
Clinical, Journal: Safety and efficacy of sargramostim (GM-CSF) in the treatment of Alzheimer's disease. (Pubmed Central) - Mar 30, 2021
P2
The innate immune system is a viable target for therapeutic intervention in AD. An extended treatment trial testing the long-term safety and efficacy of GM-CSF/sargramostim in AD is warranted.
- | Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Trial primary completion date, Surgery: Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Mar 18, 2021
P1, N=18, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
An extended treatment trial testing the long-term safety and efficacy of GM-CSF/sargramostim in AD is warranted. Trial primary completion date: Mar 2021 --> Jun 2021
- || Zeltherva (galinpepimut-S) / SELLAS Life Sciences
Trial completion date, Trial primary completion date, Metastases: Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers (clinicaltrials.gov) - Mar 17, 2021
P1/2, N=90, Recruiting, Sponsor: Sellas Life Sciences Group
Trial primary completion date: Mar 2021 --> Jun 2021 Trial completion date: Apr 2023 --> Apr 2024 | Trial primary completion date: Dec 2020 --> Jan 2024
- | Keytruda (pembrolizumab) / Merck (MSD), SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
Enrollment closed, Trial completion date, Trial primary completion date: RESURGe: Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence (clinicaltrials.gov) - Mar 16, 2021
P2, N=40, Active, not recruiting, Sponsor: David Peereboom, MD
Trial completion date: Apr 2023 --> Apr 2024 | Trial primary completion date: Dec 2020 --> Jan 2024 Recruiting --> Active, not recruiting | Trial completion date: Dec 2021 --> May 2021 | Trial primary completion date: Dec 2020 --> May 2021
- Leukine (sargramostim) / Sanofi
[VIRTUAL] White-Out Lungs: A Case of Autoimmune Pulmonary Alveolar Proteinosis () - Mar 14, 2021 - Abstract #ATS2021ATS_4784;
An elevated anti-GM CSF antibody titre is 91-98% specific for autoimmune PAP. Treatment of this condition usually involves whole lung lavage, although experimental therapy with inhaled and subcutaneous GM-CSF (sargramostim) is under investigation.
- GP2 / Greenwich LifeSci
[VIRTUAL] A prospective, randomized, multicenter, double-blinded, placebo-controlled phase III trial of the HER2/neu peptide GP2 + GM-CSF versus bacteriostatic saline/WFI placebo as adjuvant therapy after any trastuzumab-based therapy in HER2-positive women with operable breast cancer () - Mar 11, 2021 - Abstract #AACR2021AACR_3267;
The participant duration of the trial will be 3 years treatment plus 2 years follow-up for a total of 5 years following the first year treatment with trastuzumab-based therapy or approved biosimilar. An interim analysis is planned and patients will be stratified based on prior and current treatments, among other factors.Eligibility Criteria: The majority of breast cancer patients will be HER2/neu positive and HLA 2+, disease-free, conventionally treated node-positive, post breast tumor removal surgery and following the first year treatment with trastuzumab-based therapy.Trial Objectives:To determine if GP2 therapy reduces recurrence in HER2/neu positive breast cancer patients.To monitor the in vitro and in vivo immunologic responses to GP2 therapy and correlate these responses with the clinical outcomes.To monitor for any unexpected adverse events and toxicities related to GP2 therapy.Accrual: The target enrollment is up to approximately 500 patients.Contact information: snehal.patel@greenwichlifesciences.com
- | Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Enrollment closed: Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma (clinicaltrials.gov) - Mar 10, 2021
P2, N=95, Active, not recruiting, Sponsor: Children's Oncology Group
An interim analysis is planned and patients will be stratified based on prior and current treatments, among other factors.Eligibility Criteria: The majority of breast cancer patients will be HER2/neu positive and HLA 2+, disease-free, conventionally treated node-positive, post breast tumor removal surgery and following the first year treatment with trastuzumab-based therapy.Trial Objectives:To determine if GP2 therapy reduces recurrence in HER2/neu positive breast cancer patients.To monitor the in vitro and in vivo immunologic responses to GP2 therapy and correlate these responses with the clinical outcomes.To monitor for any unexpected adverse events and toxicities related to GP2 therapy.Accrual: The target enrollment is up to approximately 500 patients.Contact information: snehal.patel@greenwichlifesciences.com Recruiting --> Active, not recruiting
- | Leukine (sargramostim) / Partner Therap, SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
Trial completion date: NCI-2015-00694: SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Mar 9, 2021
P2, N=66, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Recruiting --> Active, not recruiting Trial completion date: Jan 2021 --> Dec 2021
- | Lorbrena (lorlatinib) / Pfizer, Azedra (iobenguane I 131) / Lantheus
Enrollment open: Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) (clinicaltrials.gov) - Mar 9, 2021
P3, N=813, Recruiting, Sponsor: Children's Oncology Group
Trial completion date: Jan 2021 --> Dec 2021 Active, not recruiting --> Recruiting
- | Leukine (sargramostim) / Partner Therap, SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
Trial completion date, Trial primary completion date, Metastases: Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors (clinicaltrials.gov) - Mar 5, 2021
P1, N=10, Recruiting, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Recruiting Trial completion date: Jan 2022 --> Jun 2023 | Trial primary completion date: Jan 2021 --> Jun 2022
- | Leukine (sargramostim) / Partner Therap
Trial primary completion date: Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401) (clinicaltrials.gov) - Mar 2, 2021
P2, N=203, Active, not recruiting, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Trial completion date: Jan 2022 --> Jun 2023 | Trial primary completion date: Jan 2021 --> Jun 2022 Trial primary completion date: Dec 2020 --> Aug 2021
- | Leukine (sargramostim) / Partner Therap, Neupogen (filgrastim) / Kyowa Kirin, Amgen, NN1213 / Novo Nordisk
Enrollment closed: Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis (clinicaltrials.gov) - Mar 2, 2021
P2, N=31, Active, not recruiting, Sponsor: Virginia Commonwealth University
Trial primary completion date: Dec 2020 --> Aug 2021 Recruiting --> Active, not recruiting
- || Leukine (sargramostim) / Partner Therap
Enrollment closed: iLeukPulm: Study of Sargramostim in Patients With COVID-19 (clinicaltrials.gov) - Mar 1, 2021
P2, N=122, Active, not recruiting, Sponsor: Partner Therapeutics, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Leukine (sargramostim) / Partner Therap
Trial completion, Trial primary completion date: Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC) (clinicaltrials.gov) - Mar 1, 2021
P4, N=80, Completed, Sponsor: University Hospital, Ghent
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Jan 2021 --> Sep 2020
- | EGFR bi-armed autologous activated T cells / Barbara Ann Karmanos Cancer Institute
Trial completion date, Trial primary completion date, Combination therapy, IO biomarker, Metastases: NCI-2015-01942: BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer (clinicaltrials.gov) - Mar 1, 2021
P1/2, N=2, Active, not recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Active, not recruiting --> Completed | Trial primary completion date: Jan 2021 --> Sep 2020 Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021
- | humanised dinutuximab (Hu14.18K322A) / Essential Pharma
Trial completion date, Trial primary completion date, Metastases: Therapy for Children With Advanced Stage Neuroblastoma (clinicaltrials.gov) - Feb 24, 2021
P2, N=153, Active, not recruiting, Sponsor: St. Jude Children's Research Hospital
Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021 Trial completion date: Jul 2021 --> Dec 2023 | Trial primary completion date: Jan 2021 --> Dec 2021
- | Leukine (sargramostim) / Partner Therap
Trial completion date, Trial primary completion date, Post-transplantation: GM-CSF With Post-Transplant Cyclophosphamide (clinicaltrials.gov) - Feb 21, 2021
P2, N=38, Recruiting, Sponsor: Northside Hospital, Inc.
Trial completion date: Jul 2021 --> Dec 2023 | Trial primary completion date: Jan 2021 --> Dec 2021 Trial completion date: May 2023 --> May 2024 | Trial primary completion date: May 2022 --> May 2023
- | UV1 / Ultimovacs
Trial completion date: INITIUM: UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma (clinicaltrials.gov) - Feb 17, 2021
P2, N=154, Recruiting, Sponsor: Ultimovacs ASA
Trial completion date: May 2023 --> May 2024 | Trial primary completion date: May 2022 --> May 2023 Trial completion date: Sep 2022 --> Sep 2024
- ||| Leukine (sargramostim) / Partner Therap
Trial completion date, Trial primary completion date: A Phase II/III Study of Sargramostim (clinicaltrials.gov) - Feb 10, 2021
P2/3, N=60, Recruiting, Sponsor: Nobelpharma
Trial completion date: Sep 2022 --> Sep 2024 Trial completion date: Apr 2021 --> Oct 2021 | Trial primary completion date: Apr 2021 --> Oct 2021
- | Keytruda (pembrolizumab) / Merck (MSD), Leukine (sargramostim) / Partner Therap, Yervoy (ipilimumab) / BMS
New P2 trial, Metastases: Metastatic Solid Cancer Clinical Trial (clinicaltrials.gov) - Feb 4, 2021
P2, N=32, Recruiting, Sponsor: ImmunSYS, LLC
- | Leukine (sargramostim) / Partner Therap
Trial completion: Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma (clinicaltrials.gov) - Jan 29, 2021
P2, N=327, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
Trial completion date: Apr 2021 --> Oct 2021 | Trial primary completion date: Apr 2021 --> Oct 2021 Active, not recruiting --> Completed
- | Leukine (sargramostim) / Partner Therap
Trial completion date, Trial primary completion date: Evaluation of a Single Dose of Inhaled Sargramostim in Patients With Autoimmune Pulmonary Alveolar Proteinosis (clinicaltrials.gov) - Jan 27, 2021
P1, N=10, Recruiting, Sponsor: Children's Hospital Medical Center, Cincinnati
Active, not recruiting --> Completed Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021
- || Zolinza (vorinostat) / Merck (MSD), Azedra (iobenguane I 131) / Lantheus, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Enrollment change: MIBG With Dinutuximab +/- Vorinostat (clinicaltrials.gov) - Jan 20, 2021
P1, N=32, Recruiting, Sponsor: New Approaches to Neuroblastoma Therapy Consortium
Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021 N=24 --> 32
- || Keytruda (pembrolizumab) / Merck (MSD), Leukine (sargramostim) / Partner Therap, Yervoy (ipilimumab) / BMS
New P2 trial, Metastases: ABSCOPAL 5001: A Phase 2 Trial for Patients With Metastatic Solid Cancer (clinicaltrials.gov) - Jan 18, 2021
P2, N=32, Recruiting, Sponsor: Rampart Health, L.L.C.